Coloplast presents revised 2030 ambition for annual organic growth of 5-7%
Coloplast revised its 2030 ambitions to annual organic growth of 5-7% and an EBIT margin in the mid-20% range in constant currencies. It reported FY 2025/26 revenue of DKK 28.94 billion, up 4%, and EBIT before special items of DKK 7.45 billion, down 3%.
1. Revised ambitions
Coloplast revised its 2030 ambitions to annual organic growth of 5-7%, targeting an EBIT margin in the mid-20% range in constant currencies. The company cited higher growth investments and external headwinds, and said its “Funding the Journey” program targets DKK 500 million in savings.
2. Guidance and results
For FY 2026/27, Coloplast forecasts 5-7% organic growth and an EBIT margin of around 25% before special items. In FY 2025/26, revenue rose 4% to DKK 28.94 billion, supported by Chronic Care and Interventional Urology; EBIT before special items fell 3% to DKK 7.45 billion, reflecting currency headwinds and pressure from Kerecis.
